Aethlon Medical has filed a patent for devices and methods that can capture and remove COVID-19 mediating nanoparticles and exosomes from the circulatory system of patients, including those with post-COVID-19 syndrome. The invention involves using lectin-based extracorporeal methods to bind and physically remove SARS-CoV-2 virions and non-viral COVID-19 mediating nanoparticles. The patent also includes devices and methods for reducing biomarkers and markers of morbidity/mortality associated with COVID-19. The claim outlines a method for reducing SARS-CoV-2 virions in COVID-19 patients by introducing their blood or plasma into an extracorporeal device containing a lectin that binds to the virions, allowing them to bind to the lectin, and then reintroducing the blood or plasma back into the patient with a reduced amount of virions. Optional steps include detecting or identifying the virions in patient samples and selecting patients for therapy based on the presence of virions. GlobalData’s report on Aethlon Medical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Aethlon Medical, wearable breast pumps was a key innovation area identified from patents. Aethlon Medical's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Method for removing covid-19 particles from patient's blood
A recently filed patent (Publication Number: US20230158222A1) describes a method for reducing SARS-CoV-2 virions, or portions thereof, in COVID-19 patients. The method involves several steps to achieve this reduction.
The first step of the method involves introducing blood or plasma from a patient infected with COVID-19 into an extracorporeal device. This device contains a lectin that specifically binds to SARS-CoV-2 virions, or portions thereof. The blood or plasma from the patient is then contacted with the lectin in the extracorporeal device for a sufficient amount of time to allow the SARS-CoV-2 virions to bind to the lectin.
After this binding process, the blood or plasma obtained from the extracorporeal device is reintroduced into the patient. It is important to note that the blood or plasma obtained after the binding process has a reduced amount of SARS-CoV-2 virions compared to the blood or plasma of the patient prior to the binding process.
Additionally, the method allows for the optional detection or identification of SARS-CoV-2 virions in a sample from the patient, such as a nasal swab, blood, or plasma sample. This detection or identification can be done before the introduction of blood or plasma into the extracorporeal device, after the binding process, or both. Furthermore, the method also allows for the optional selection or identification of patients with COVID-19 who would benefit from a therapy that reduces SARS-CoV-2 virions or fragments thereof.
It is important to note that claims 2-69 of the patent have been canceled and are not included in the summary.
In summary, the filed patent describes a method for reducing SARS-CoV-2 virions in COVID-19 patients. The method involves using an extracorporeal device with a lectin that binds to the virions, allowing them to be removed from the patient's blood or plasma. The blood or plasma is then reintroduced into the patient, resulting in a reduced amount of virions. The method also allows for the optional detection or identification of virions in patient samples and the selection of patients for specific therapies.